O001 Reboxetine reduces obstructive sleep apnea severity: a randomized trial

INTRODUCTION: Noradrenergic and muscarinic processes are crucial for pharyngeal muscle control during sleep. Selective norepinephrine reuptake inhibitors (SNRIs) such as reboxetine combined with an antimuscarinic reduce obstructive sleep apnea (OSA) severity. The effects of reboxetine alone on OSA s...

Descripción completa

Detalles Bibliográficos
Autores principales: Altree, T, Aishah, A, Loffler, K, Grunstein, R, Eckert, D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Oral Presentations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108629/
http://dx.doi.org/10.1093/sleepadvances/zpab014.000

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108629/
http://dx.doi.org/10.1093/sleepadvances/zpab014.000

Ejemplares similares